Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Metabolism
  4. Volume 25, Issue 5
  5. Article
Volume 25, Issue 5
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Background

Small heterocyclic compounds have been crucial in pioneering advances in type 2 diabetes treatment. There has been a dramatic increase in the pharmacological development of novel heterocyclic derivatives aimed at stimulating the activation of Glucokinase (GK). A pharmaceutical intervention for diabetes is increasingly targeting GK as a legitimate target. Diabetes type 2 compromises Glucokinase's function, an enzyme vital for maintaining the balance of blood glucose levels. Medicinal substances strategically positioned to improve type 2 diabetes management are used to stimulate the GK enzyme using heterocyclic derivatives.

Objective

The research endeavor aimed to craft novel compounds, drawing inspiration from the inherent coumarin nucleus found in nature. The goal was to evoke the activity of the glucokinase enzyme, offering a tailored approach to mitigate the undesired side effects typically associated with conventional therapies employed in the treatment of type 2 diabetes.

Methods

Coumarin, sourced from nature's embrace, unfolds as a potent and naturally derived ally in the quest for innovative antidiabetic interventions. Coumarin was extracted from a variety of botanical origins, including Artemisia keiskeana, Mallotus resinosus, Jatropha integerrima, Ferula tingitana, Zanthoxylum schinifolium, Phebalium clavatum, and Mammea siamensis. This inclusive evaluation was conducted on Muybridge's digital database containing 53,000 hit compounds. The presence of the coumarin nucleus was found in 100 compounds, that were selected from this extensive repository. Utilizing Auto Dock Vina 1.5.6 and ChemBioDraw Ultra, structures generated through this process underwent docking analysis. Furthermore, these compounds were accurately predicted online log P using the Swiss ADME algorithm. A predictive analysis was conducted using PKCSM software on the primary compounds to assess potential toxicity.

Results

Using Auto Dock Vina 1.5.6, 100 coumarin derivatives were assessed for docking. Glucokinase (GK) binding was significantly enhanced by most of these compounds. Based on superior binding characteristics compared with Dorzagliatin (standard GKA) and MRK (co-crystallized ligand), the top eight molecules were identified. After further evaluation through ADMET analysis of these eight promising candidates, it was confirmed that they met the Lipinski rule of five and their pharmacokinetic profile was enhanced. The highest binding affinity was demonstrated by APV16 at -10.6 kcal/mol. A comparison between the APV16, Dorzagliatin and MRK in terms of toxicity predictions using PKCSM indicated that the former exhibited less skin sensitization, AMES toxicity, and hepatotoxicity.

Conclusion

Glucokinase is most potently activated by 100 of the compound leads in the database of 53,000 compounds that contain the coumarin nucleus. APV12, with its high binding affinity, favorable ADMET (adjusted drug metabolic equivalents), minimal toxicity, and favorable pharmacokinetic profile warrants consideration for progress to testing. Nevertheless, to uncover potential therapeutic implications, particularly in the context of type 2 diabetes, thorough investigations and evaluations are necessary for benchmarking before therapeutic use, especially experiments involving the STZ diabetic rat model.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002321919240801065905
2024-08-06
2024-12-23

  • From This Site

    /content/journals/cdm/10.2174/0113892002321919240801065905
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MustafaY.F. IsmaelR.N. JebirR.M. Natural coumarins from two cultivars of watermelon seeds as biosafe anticancer agents, An algorithm for their isolation and evaluation.J. Mol. Struct.2024129513664410.1016/j.molstruc.2023.136644
     [Google Scholar]
  2. PanY. LiuT. WangX. SunJ. Research progress of coumarins and their derivatives in the treatment of diabetes.J. Enzyme Inhib. Med. Chem.202237161662810.1080/14756366.2021.2024526 35067136
     [Google Scholar]
  3. RanđelovićS. BipatR. A review of coumarins and coumarin-related compounds for their potential antidiabetic effect.Clin. Med. Insights Endocrinol. Diabetes20211410.1177/11795514211042023 35173509
     [Google Scholar]
  4. KonidalaS.K. KotraV. DandugaR.C.S.R. KolaP.K. Coumarin-chalcone hybrids targeting insulin receptor: Design, synthesis, anti-diabetic activity, and molecular docking.Bioorg. Chem.202010410420710.1016/j.bioorg.2020.104207 32947135
     [Google Scholar]
  5. AnnunziataF. PinnaC. DallavalleS. TamboriniL. PintoA. An overview of coumarin as a versatile and readily accessible scaffold with broad-ranging biological activities.Int. J. Mol. Sci.20202113461810.3390/ijms21134618 32610556
     [Google Scholar]
  6. HussainM.I. SyedQ.A. KhattakM.N.K. HafezB. ReigosaM.J. El-KeblawyA. Natural product coumarins: Biological and pharmacological perspectives.Biologia (Bratisl.)201974786388810.2478/s11756‑019‑00242‑x
     [Google Scholar]
  7. Şahı̇nH. In-vitro anti-diabetic, anti-alzheimer, anti-tyrosinase, antioxidant activities of selected coumarin and dihydroisocoumarin derivatives.Int. J. Sec. Metabol.202310336136910.21448/ijsm.1196712
     [Google Scholar]
  8. VawhalP.K. JadhavS.B. KaushikS. PanigrahiK.C. NayakC. UrmeeH. KhanS.L. SiddiquiF.A. IslamF. EftekhariA. AlzahraniA.R. AzlinaM.F.N. SarkerM.M.R. IbrahimI.A.A. Coumarin-based sulfonamide derivatives as potential dpp-iv inhibitors: pre-adme analysis, toxicity profile, computational analysis, and in vitro enzyme assay.Molecules2023283100410.3390/molecules28031004 36770672
     [Google Scholar]
  9. IsmaelR. MustafaY. Al-QazazH. Coumarin-based products: Their biodiversity and pharmacology.Iraqi J. Pharma.202218216217910.33899/iphr.2022.170405
     [Google Scholar]
  10. Sharifi-RadJ. Cruz-MartinsN. López-JornetP. LopezE.P. HarunN. YeskaliyevaB. BeyatliA. SytarO. ShaheenS. SharopovF. Taheri, Y Natural coumarins: Exploring the pharmacological complexity and underlying molecular mechanisms.Oxid. Med. Cell. Longev.2021649234610.1155/2021/6492346
     [Google Scholar]
  11. Kumar PasalaV. GudipudiG. SankeshiV. BasudeM. GundlaR. singh Jadav, S.; Srinivas, B.; Yadaiah Goud, E.; Nareshkumar, D. Design, synthesis and biological evaluation of selective hybrid coumarin-thiazolidinedione aldose reductase-II inhibitors as potential antidiabetics.Bioorg. Chem.202111410497010.1016/j.bioorg.2021.104970 34120026
     [Google Scholar]
  12. Al-SofianiM.E. AsiriA. AlajmiS. AlkeridyW. Perspectives on prediabetes and aging.Endocrinol. Metab. Clin. North Am.202352237738810.1016/j.ecl.2022.10.011 36948785
     [Google Scholar]
  13. AbdumannabovnaK.A. IlkhomzonovichF.I. NematjonovnaF.K. SergeevnaA.B. The role of diet and preventive nutrition in diabetes type 2.Central Asian J. Med. Nat. Sci.202232324328
     [Google Scholar]
  14. LeslieR.D. PalmerJ. SchlootN.C. LernmarkA. Diabetes at the crossroads: Relevance of disease classification to pathophysiology and treatment.Diabetologia2016591132010.1007/s00125‑015‑3789‑z 26498592
     [Google Scholar]
  15. NugrohoP. AndrewH. KoharK. NoorC.A. SutrantoA.L. Comparison between the world health organization (WHO) and international society of hypertension (ISH) guidelines for hypertension.Ann. Med.202254183784510.1080/07853890.2022.2044510 35291891
     [Google Scholar]
  16. UturaT. FikrieA. Prevalence and associated factors of diabetes mellitus among governmental civil servants at Guji Zone, Oromia Region, Ethiopia, 2021. A community-based cross-sectional study.PLoS One202217426723110.1371/journal.pone.0267231 35427392
     [Google Scholar]
  17. ZimmetP.Z. Kelly West Lecture 1991. Challenges in diabetes epidemiology-from west to the rest.Diabetes Care199215223225210.2337/diacare.15.2.232 1547680
     [Google Scholar]
  18. MehraA. MehraA. Antidiabetic advancements in silico: Pioneering novel heterocyclic derivatives through computational design.Curr. Signal Transduct. Ther.2024192617110.2174/0115743624282326240418104054
     [Google Scholar]
  19. ZimmetP. TaylorR. RamP. KingH. SlomanG. RaperL.R. HuntD. Prevalence of diabetes and impaired glucose tolerance in the biracial (Melanesian and Indian) population of Fiji: A rural-urban comparison.Am. J. Epidemiol.1983118567368810.1093/oxfordjournals.aje.a113678 6637994
     [Google Scholar]
  20. YangK. WangY. LiY. ChenY. XingN. LinH. ZhouP. YuX. Progress in the treatment of diabetic peripheral neuropathy.Biomed. Pharmacother.202214811271710.1016/j.biopha.2022.112717 35193039
     [Google Scholar]
  21. RadhaV. KanthimathiS. AmuthaA. BhavadhariniB. AnjanaR.M. UnnikrishnanR. MohanV. Monogenic diabetes reported in So uth Asians: A systematic review.J. Indian Inst. Sci.2023103130933410.1007/s41745‑023‑00399‑0
     [Google Scholar]
  22. Diagnosis and classification of diabetes mellitus.Diabetes Care201437S81S9010.2337/dc14‑S081 24357215
     [Google Scholar]
  23. ThunanderM. TörnC. PeterssonC. OssianssonB. FornanderJ. Landin-OlssonM. Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden.Eur. J. Endocrinol.201216661021102910.1530/EJE‑11‑0797 22436402
     [Google Scholar]
  24. RosenbloomA.L. SilversteinJ.H. AmemiyaS. ZeitlerP. KlingensmithG.J. Type 2 diabetes in children and adolescents.Pediatr. Diabetes200910173210.1111/j.1399‑5448.2009.00584.x 19754615
     [Google Scholar]
  25. CakanN. KizilbashS. KamatD. Changing spectrum of diabetes mellitus in children: Challenges with initial classification.Clin. Pediatr. (Phila.)2012511093994410.1177/0009922812441666 22496179
     [Google Scholar]
  26. WilkinT.J. The accelerator hypothesis: A review of the evidence for insulin resistance as the basis for type I as well as type II diabetes.Int. J. Obes.200933771672610.1038/ijo.2009.97
     [Google Scholar]
  27. CanivellS. GomisR. Diagnosis and classification of autoimmune diabetes mellitus.Autoimmun. Rev.2014134-540340710.1016/j.autrev.2014.01.020 24424179
     [Google Scholar]
  28. LambM.M. YinX. ZerbeG.O. KlingensmithG.J. DabeleaD. FingerlinT.E. RewersM. NorrisJ.M. Height growth velocity, islet autoimmunity and type 1 diabetes development: The diabetes autoimmunity study in the young.Diabetologia200952102064207110.1007/s00125‑009‑1428‑2 19547949
     [Google Scholar]
  29. VehikK. HammanR.F. LezotteD. NorrisJ.M. KlingensmithG.J. DabeleaD. Childhood growth and age at diagnosis with type 1 diabetes in Colorado young people.Diabet. Med.2009261096196710.1111/j.1464‑5491.2009.02819.x 19900226
     [Google Scholar]
  30. KalraS. MithalA. ZargarA.H. SethiB. DharmalingamM. GhoshS. SenR. Indian phenotype characteristics among patients with type 2 diabetes mellitus: Insights from a non-interventional nationwide registry in India.Touch Rev. Endocrinology202218163
     [Google Scholar]
  31. PerlS. KushnerJ.A. BuchholzB.A. MeekerA.K. SteinG.M. HsiehM. KirbyM. PechholdS. LiuE.H. HarlanD.M. TisdaleJ.F. Significant human β-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating.J. Clin. Endocrinol. Metab.2010951023423910.1210/jc.2010‑0932 20660050
     [Google Scholar]
  32. DavisT.M.E. MakepeaceA.E. EllardS. ColcloughK. PetersK. HattersleyA. DavisW.A. The prevalence of monogenic diabetes in Australia: The fremantle diabetes study phase II.Med. J. Aust.2017207834434710.5694/mja16.01201 29020906
     [Google Scholar]
  33. WoodmanseyC. McGovernA.P. McCulloughK.A. WhyteM.B. MunroN.M. CorreaA.C. GatenbyP.A.C. JonesS.A. de LusignanS. Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (type 3c): A retrospective cohort study.Diabetes Care201740111486149310.2337/dc17‑0542 28860126
     [Google Scholar]
  34. SunH. SaeediP. KarurangaS. PinkepankM. OgurtsovaK. DuncanB.B. SteinC. BasitA. ChanJ.C.N. MbanyaJ.C. PavkovM.E. RamachandaranA. WildS.H. JamesS. HermanW.H. ZhangP. BommerC. KuoS. BoykoE.J. MaglianoD.J. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Diabetes Res. Clin. Pract.202218310911910.1016/j.diabres.2021.109119 34879977
     [Google Scholar]
  35. RooneyM.R. FangM. OgurtsovaK. OzkanB. Echouffo-TcheuguiJ.B. BoykoE.J. MaglianoD.J. SelvinE. Global prevalence of prediabetes.Diabetes Care20234671388139410.2337/dc22‑2376 37196350
     [Google Scholar]
  36. SuJ. LuoY. HuS. TangL. OuyangS. Advances in research on type 2 diabetes mellitus targets and therapeutic agents.Int. J. Mol. Sci.202324171338110.3390/ijms241713381 37686185
     [Google Scholar]
  37. YangW. JiangW. GuoS. Regulation of macronutrients in insulin resistance and glucose homeostasis during type 2 diabetes mellitus.Nutrients20231521467110.3390/nu15214671 37960324
     [Google Scholar]
  38. AhmadE. LimS. LampteyR. WebbD.R. DaviesM.J. Type 2 diabetes.Lancet2022400103651803182010.1016/S0140‑6736(22)01655‑5 36332637
     [Google Scholar]
  39. ButtS.M. Management and treatment of type 2 diabetes Int.J. Comp. Info. Manufac.202221
     [Google Scholar]
  40. DeMarsilisA. ReddyN. BoutariC. FilippaiosA. SternthalE. KatsikiN. MantzorosC. Pharmacotherapy of type 2 diabetes: An update and future directions.Metabolism202213715533210.1016/j.metabol.2022.155332 36240884
     [Google Scholar]
  41. DeForestN. MajithiaA.R. Genetics of type 2 diabetes: Implications from large-scale studies.Curr. Diab. Rep.202222522723510.1007/s11892‑022‑01462‑3 35305202
     [Google Scholar]
  42. MizukamiH. KudohK. Diversity of pathophysiology in type 2 diabetes shown by islet pathology.J. Diabetes Investig.202213161310.1111/jdi.13679 34562302
     [Google Scholar]
  43. LimaJ.E.B.F. MoreiraN.C.S. Sakamoto-HojoE.T. Mechanisms underlying the pathophysiology of type 2 diabetes: From risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia.Mutat. Res. Genet. Toxicol. Environ. Mutagen.2022874-87550343710.1016/j.mrgentox.2021.503437 35151421
     [Google Scholar]
  44. RenY. LiL. WanL. HuangY. CaoS. Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists.J. Enzyme Inhib. Med. Chem.202237160661510.1080/14756366.2021.2025362 35067153
     [Google Scholar]
  45. KaurA. ThakurS. DeswalG. ChopraB. DhingraA.K. GuarveK. GrewalA.S. In silico docking based screening of constituents from Persian shallot as modulators of human glucokinase.J. Diabetes Metab. Disord.202222154757010.1007/s40200‑022‑01176‑z 37255832
     [Google Scholar]
  46. GaoQ. ZhangW. LiT. YangG. ZhuW. ChenN. JinH. The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus.Medicine (Baltimore)2021100402747610.1097/MD.0000000000027476 34622877
     [Google Scholar]
  47. W, Yang evaluation of efficacy and safety of glucokinase activators-a systematic review and meta-analysis.Front. Endocrinol.2023141175198
     [Google Scholar]
  48. LiuJ. FuH. KangF. NingG. NiQ. WangW. WangQ. β‐Cell glucokinase expression was increased in type 2 diabetes subjects with better glycemic control.J. Diabetes202315540941810.1111/1753‑0407.13380 36942376
     [Google Scholar]
  49. PaliwalA. PaliwalV. JainS. PaliwalS. SharmaS. Current insight on the role of glucokinase and glucokinase regulatory protein in diabetes.Mini Rev. Med. Chem.202424767468810.2174/1389557523666230823151927 37612862
     [Google Scholar]
  50. ChakeraA.J. SteeleA.M. GloynA.L. ShepherdM.H. ShieldsB. EllardS. HattersleyA.T. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation.Diabetes Care20153871383139210.2337/dc14‑2769 26106223
     [Google Scholar]
  51. SongL. CaoF. NiuS. XuM. LiangR. DingK. LinZ. YaoX. LiuD. Population pharmacokinetic/pharmacodynamic analysis of the glucokinase activator pb201 in healthy volunteers and patients with type 2 diabetes mellitus: Facilitating the clinical development of pb201 in China.Clin. Pharmacokinet.2023202316 37985591
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002321919240801065905
Loading
Prediction of Protein-Drug Interactions, Pharmacophore Modeling, and Toxicokinetics of Novel Leads for Type 2 Diabetes Treatment
Current Drug Metabolism 25, 355 (2024); https://doi.org/10.2174/0113892002321919240801065905
/content/journals/cdm/10.2174/0113892002321919240801065905
/content/journals/cdm/10.2174/0113892002321919240801065905
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): coumarin derivatives; drug design; glucokinase; pharmacophore; Type 2 diabetes; virtual screening

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test